Legend Biotech Reports Accelerating CARVYKTI Sales and Path to Profitability

Biotech firm highlights global demand growth, manufacturing expansion, and improving financial metrics for its multiple myeloma treatment.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Legend Biotech (NASDAQ:LEGN) executives detailed accelerating global demand for the company's CARVYKTI CAR-T therapy, improving profitability metrics, and expanding manufacturing capacity during the firm's fourth quarter 2025 earnings call. Management said CARVYKTI reached profitability in 2025 and the company expects to be profitable on an enterprise-wide basis in 2026.

Why it matters

As a leading developer of CAR-T cancer treatments, Legend Biotech's performance and outlook for its flagship CARVYKTI product provide important insights into the growth and evolution of this innovative therapeutic approach. The company's progress in expanding global access, improving manufacturing efficiency, and achieving profitability milestones underscore the commercial viability of its technology.

The details

Legend Biotech reported that CARVYKTI net trade sales were approximately $555 million in the fourth quarter, up 66% year-over-year. Growth was supported by continued market share gains, site expansion, and broader geographic availability, with CARVYKTI now offered in 14 global markets and supported by 294 treatment sites. In the U.S., sales reached $420 million, up 38% year-over-year, while international markets more than tripled to $135 million. Management emphasized that CARVYKTI utilization is shifting earlier in the treatment course, with around 65% of patients now receiving it in the second- to fourth-line setting.

  • CARVYKTI's Tech Lane facility in Belgium began commercial production in September 2025 to serve ex-U.S. markets.
  • Legend Biotech and Johnson & Johnson are planning to supply up to 20,000 CARVYKTI doses into U.S. and European markets through ongoing capital expenditures.

The players

Ying Huang

Chief Executive Officer of Legend Biotech.

Alan Bash

President of CARVYKTI at Legend Biotech.

Carlos Santos

Chief Financial Officer of Legend Biotech.

Anita D'Souza

Researcher who published a study on the use of talquetamab bridging therapy with CARVYKTI.

Surbhi Sidana

Researcher who led a study on Parkinsonism cases in CARVYKTI-treated patients.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.